u/iman_castellanos

stalled at 12.5mg, went up, and regretted it, the stall would have broken anyway

Yes, exactly this, and it is the bit that took me 72 weeks to accept.

triple agonism is phase 2, do not generalise

Is that absolute or relative risk reduction?

long-acting amylin is CagriSema, different satiety profile

The fatigue was genuinely awful for three weeks and then simply stopped.

Disagree on that part. 97.4% and 98.7% on the same vial is normal.

Yeah, 78 weeks on 5mg, same pattern, same timing.

heart rate and dose escalation need actual measurements, not impressions

the quiet is real. the food noise just stops.

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

Crossposting this to c/bloodwork because the people who need it are not reading this community.

Ireland here. Waited 18 months on a list, gave up, went private, and the total cost was roughly what I expected.

The thing nobody prepared me for was the quiet. Not the appetite, the quiet. The constant negotiation in my head about food just stopped.

insulin and sulfonylurea interactions are real hypo risk

Not convinced. The evidence does not support that reading.

That is net peptide content, not purity. Different number, different meaning.

Slight fix: the number was 99.0, not 98.9. Decimal point, but a fairly consequential one.

Every time this gets posted it hits the front page and every time someone has to re-explain it.

the 11mg import allowance is Denmark-specific

This is correct. The co-agonism is real.